What is MIRA1a?

A Novel Synthetic THC Analog

MIRA1a is being developed as the first prescription drug to target the cannabinoid receptors CB1 and CB2 for neuropathic pain, anxiety and cognitive enhancements without the impurities of marijuana or its side effects such as increased appetite and paranoia.

View MIRA1a Video


New molecular entity with a 20-year patent life.


Manufactured rather than extracted or purified.


Combines the best potential benefits of tetrahydrocannabinol (THC) and cannabidiol (CBD) and neutralizes their side effects.


Its unique structure and properties are different from existing cannabinoids.

Making a Better Molecule

MIRA1a, a revolutionary new compound, solves three central challenges in cannabinoid drug development.

  • How to enhance the beneficial effects of THC and CBD compounds.
  • How to combine the optimal effects of both compounds.
  • How to minimize the negative effects of THC.

MIRA1a answers these challenges with a single powerful molecule that's different from THC and CBD while combining the well-known therapeutic potential of both.

The Challenge with CBD and THC

Originally derived from the cannabis plant in the form of marijuana, THC and CBD have been used as medicine for millennia. Marijuana or natural cannabis contains several times more THC than CBD.

While THC and CBD have nearly identical molecular structures, they interact differently with the body’s endocannabinoid system to cause unique effects. THC can cause unwanted side effects.


CBD does not bring about these negative side effects and may actually help counteract them. CBD has been shown to help treat anxiety, pain and seizures.


THC can bring about a “high” or feeling of euphoria. But for some, it can also lead to negative moods, impaired memory, increased appetite and paranoia.

The Benefits of MIRA1a


MIRA1a is manufactured rather than extracted or purified.


MIRA1a offers a wider therapeutic window and increases CB2 activation.


MIRA1a increases efficacy while minimizing the side effects of THC.


There is a need for less risky cannabinoid therapeutics like MIRA1a.


MIRA1a is fully patented as a novel chemical entity.

Our Research

Find out more about our research and publications featuring MIRA1a.

View Our Research & Publications